We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics
ALDX

24 hedge funds and large institutions have $32.9M invested in Aldeyra Therapeutics in 2015 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

900% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 1

133% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 3

89% more capital invested

Capital invested by funds: $17.4M → $32.9M (+$15.4M)

60% more funds holding

Funds holding: 15 → 24 (+9)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
24
Holders Change
+9
Holders Change %
+60%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
10
Increased
7
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
DM
Deerfield Management
New York
+$5.95M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.2M
3
PA
Perceptive Advisors
New York
+$4.42M
4
SM
Sabby Management
Florida
+$2.3M
5
SFM
Sphera Funds Management
Israel
+$1.29M

Top Sellers

1
DCM
DAFNA Capital Management
California
-$356K
2
Deutsche Bank
Deutsche Bank
Germany
-$21.6K
3
TRCT
Tower Research Capital (TRC)
New York
-$8.83K
4
SIM
Spark Investment Management
New York
-$6.04K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$11.2M +$5.2M +603,000 +72%
PA
2
Perceptive Advisors
New York
$6.75M +$4.42M +512,800 +144%
DM
3
Deerfield Management
New York
$5.36M +$5.95M +690,538 New
SM
4
Sabby Management
Florida
$2.07M +$2.3M +266,953 New
SFM
5
Sphera Funds Management
Israel
$2.06M +$1.29M +150,000 +130%
BBA
6
Baker Bros. Advisors
New York
$1.1M – – –
KCM
7
Knoll Capital Management
Florida
$1.05M – – –
Millennium Management
8
Millennium Management
New York
$923K +$1.03M +119,000 New
Vanguard Group
9
Vanguard Group
Pennsylvania
$802K +$892K +103,470 New
PVI
10
Pura Vida Investments
New York
$511K +$496K +57,500 New
NIP
11
Nicholas Investment Partners
California
$317K +$280K +32,455 +389%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$175K – – –
SIM
13
Spark Investment Management
New York
$170K -$6.04K -700 -3%
WMSA
14
Weiss Multi-Strategy Advisers
New York
$136K +$151K +17,500 New
Morgan Stanley
15
Morgan Stanley
New York
$128K +$23K +2,663 +19%
Northern Trust
16
Northern Trust
Illinois
$86K +$95.8K +11,106 New
VIA
17
Vantage Investment Advisors
Pennsylvania
$16K +$17.2K +2,000 New
UBS Group
18
UBS Group
Switzerland
$15K +$14.8K +1,713 +820%
BA
19
BlackRock Advisors
Delaware
$9K +$10.2K +1,184 New
BIM
20
BlackRock Investment Management
Delaware
$7K +$5.94K +689 +256%
IF
21
Ironwood Financial
Arizona
$4K – – –
Walleye Trading
22
Walleye Trading
New York
$3K +$3.45K +400 New
TRCT
23
Tower Research Capital (TRC)
New York
$2K -$8.83K -1,024 -82%
DCM
24
DAFNA Capital Management
California
– -$356K -35,000 Closed
Deutsche Bank
25
Deutsche Bank
Germany
– -$21.6K -2,501 -99%

ALDX Hedge Fund Activity: Q2 2015 in Review

24 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q2 2015, worth a combined $32.9M — up 89% from $17.4M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new ALDX positions and 1 closed out — a net gain of 9 holders — while 7 added to existing stakes and 3 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $5.95M. The largest seller was DAFNA Capital Management, exiting entirely with an estimated $356K sold.

  • 24 institutional investors held Aldeyra Therapeutics (ALDX) as of Q2 2015, up from 15 in Q1 2015.
  • Funds reported $32.9M of Aldeyra Therapeutics stock for Q2 2015, up 89% quarter-over-quarter.
  • 10 funds opened new Aldeyra Therapeutics positions in Q2 2015 and 1 closed out, a net change of +9 holders.
  • The largest Aldeyra Therapeutics buyer in Q2 2015 was Deerfield Management, an estimated $5.95M added.
  • The largest Aldeyra Therapeutics seller in Q2 2015 was DAFNA Capital Management, an estimated $356K sold.

Based on aggregated 13F filings for Q2 2015.